SMALL CELL LUNG CÁNCER EXTENSIVE-STAGE EN SEGUNDA LINEA . La Adición del Virus Vaccinia Oncolítico Modificado Olvimulogen Nanivacirepvec ( Olvi-vec; GL-ONC1 ) a la QUIMIOTERAPIA Basada en PLATINO y ETOPÓSIDO Condujo al Control de la Enfermedad en un 71% de Pacientes Chinos ..

Olvi-Vec Plus Chemo Yields Disease Control in Platinum-Relapsed or -Refractory ES-SCLC .

Mar 25, 2025 .

By Chris Ryan .

• Olvi-vec combined with chemotherapy achieved a 71% disease control rate in platinum-relapsed or -refractory ES-SCLC patients .
• The safety profile of olvi-vec was manageable, with most treatment-related adverse effects being mild to moderate .
• The trial is evaluating olvi-vec's efficacy, safety, and potential combinations with other agents in ES-SCLC .
• Olvi-vec's antitumor activity offers potential benefits for heavily pretreated patients with relapsed or refractory ES-SCLC .

....